<?xml version='1.0' encoding='utf-8'?>
<document id="30358688"><sentence text="Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice." /><sentence text="Vicagrel, a novel acetate analogue of clopidogrel, exerts more potent antiplatelet effect than clopidogrel in rodents"><entity charOffset="0-8" id="DDI-PubMed.30358688.s2.e0" text="Vicagrel" /><entity charOffset="18-25" id="DDI-PubMed.30358688.s2.e1" text="acetate" /><entity charOffset="38-49" id="DDI-PubMed.30358688.s2.e2" text="clopidogrel" /><entity charOffset="95-106" id="DDI-PubMed.30358688.s2.e3" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e0" e2="DDI-PubMed.30358688.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e0" e2="DDI-PubMed.30358688.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e0" e2="DDI-PubMed.30358688.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e0" e2="DDI-PubMed.30358688.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e1" e2="DDI-PubMed.30358688.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e1" e2="DDI-PubMed.30358688.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e1" e2="DDI-PubMed.30358688.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e2" e2="DDI-PubMed.30358688.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30358688.s2.e2" e2="DDI-PubMed.30358688.s2.e3" /></sentence><sentence text=" Relevant evidence indicated that aspirin and vicagrel are the drug substrate for carboxylesterase 2"><entity charOffset="34-41" id="DDI-PubMed.30358688.s3.e0" text="aspirin" /></sentence><sentence text=" Accordingly, it is deduced that concomitant use of aspirin could attenuate the bioactivation of and platelet response to vicagrel"><entity charOffset="52-59" id="DDI-PubMed.30358688.s4.e0" text="aspirin" /></sentence><sentence text=" To clarify whether there could be such an important drug-drug interaction, the differences in both the formation of vicagrel active metabolite H4 and the inhibition of adenosine diphosphate-induced platelet aggregation by vicagrel were measured and compared between mice treated with vicagrel alone or in combination with aspirin"><entity charOffset="169-190" id="DDI-PubMed.30358688.s5.e0" text="adenosine diphosphate" /><entity charOffset="323-330" id="DDI-PubMed.30358688.s5.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30358688.s5.e0" e2="DDI-PubMed.30358688.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30358688.s5.e0" e2="DDI-PubMed.30358688.s5.e1" /></sentence><sentence text=" The plasma H4 concentration was determined by liquid chromatography-tandem mass spectrometry, and the inhibition of platelet aggregation by vicagrel was assessed by whole-blood platelet aggregation" /><sentence text=" Compared with vicagrel (2"><entity charOffset="15-23" id="DDI-PubMed.30358688.s7.e0" text="vicagrel" /></sentence><sentence text="5 mg·kg) alone, concurrent use of aspirin (5, 10, or 20 mg·kg) significantly decreased systemic exposure of H4, an average of 38% and 41% decrease in Cmax and AUC0-∞ in mice when in combination with aspirin at 10 mg·kg, respectively"><entity charOffset="34-41" id="DDI-PubMed.30358688.s8.e0" text="aspirin" /><entity charOffset="199-206" id="DDI-PubMed.30358688.s8.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30358688.s8.e0" e2="DDI-PubMed.30358688.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30358688.s8.e0" e2="DDI-PubMed.30358688.s8.e1" /></sentence><sentence text=" Furthermore, concomitant use of aspirin (10 mg·kg) and vicagrel (2"><entity charOffset="33-40" id="DDI-PubMed.30358688.s9.e0" text="aspirin" /><entity charOffset="56-64" id="DDI-PubMed.30358688.s9.e1" text="vicagrel" /><pair ddi="false" e1="DDI-PubMed.30358688.s9.e0" e2="DDI-PubMed.30358688.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30358688.s9.e0" e2="DDI-PubMed.30358688.s9.e1" /></sentence><sentence text="5 mg·kg) resulted in an average of 66% reduction in the inhibition of adenosine diphosphate-induced platelet aggregation by vicagrel"><entity charOffset="70-91" id="DDI-PubMed.30358688.s10.e0" text="adenosine diphosphate" /></sentence><sentence text=" We conclude that aspirin significantly attenuates the formation of vicagrel active metabolite H4 and platelet response to vicagrel in mice, and that such an important drug-drug interaction would appear in clinical settings if vicagrel is taken with aspirin concomitantly when marketed in the future"><entity charOffset="18-25" id="DDI-PubMed.30358688.s11.e0" text="aspirin" /><entity charOffset="250-257" id="DDI-PubMed.30358688.s11.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30358688.s11.e0" e2="DDI-PubMed.30358688.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30358688.s11.e0" e2="DDI-PubMed.30358688.s11.e1" /></sentence><sentence text="" /></document>